Ocular Therapeutix, Inc. (OCUL) 追踪市盈率为负值 -7.2, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 前瞻市盈率 201.1 基于分析师预估，预计将恢复盈利。 追踪盈利收益率为 -13.83%, 前瞻盈利收益率 0.50%. PEG 0.06 (Peter Lynch 低估标准 ≤1.0).
本页证实的标准:
SharesGrow 综合评分： 49/100 其中 2/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -4.6 | -0.88 | 3.99 | 110.08 | - |
| 2017 | -2.0 | -0.09 | 4.90 | 66.69 | - |
| 2018 | -2.6 | 0.09 | 4.23 | 76.23 | - |
| 2019 | -2.1 | -0.10 | -49.26 | 42.31 | - |
| 2020 | -8.1 | -0.24 | 16.53 | 72.26 | - |
| 2021 | -81.3 | 1.38 | 6.05 | 12.23 | - |
| 2022 | -3.0 | 3.19 | 6.11 | 4.20 | - |
| 2023 | -4.4 | -0.92 | 3.91 | 6.09 | - |
| 2024 | -7.0 | -0.59 | 4.29 | 21.21 | - |
| 2025 | -8.5 | -0.52 | 3.47 | 43.86 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $-1.80 | $1.89M | $-44.7M | -2369% |
| 2017 | $-2.20 | $1.92M | $-63.39M | -3296.2% |
| 2018 | $-1.51 | $1.99M | $-57.69M | -2899.1% |
| 2019 | $-1.99 | $4.23M | $-89.94M | -2127.6% |
| 2020 | $-2.63 | $17.4M | $-159.63M | -917.3% |
| 2021 | $-0.13 | $43.52M | $-10.8M | -24.8% |
| 2022 | $-0.83 | $51.49M | $-63.42M | -123.2% |
| 2023 | $-1.02 | $58.44M | $-80.74M | -138.1% |
| 2024 | $-1.22 | $63.72M | $-193.51M | -303.7% |
| 2025 | $-1.42 | $51.82M | $-265.94M | -513.2% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $-1.35 | $-1.50 – $-1.13 | $56.74M | $55.41M – $59.22M | 7 |
| 2027 | $-1.25 | $-1.69 – $-0.64 | $115.07M | $59.4M – $273.07M | 6 |
| 2028 | $-0.99 | $-1.98 – $0.17 | $278.18M | $273.7M – $282.65M | 6 |
| 2029 | $0.04 | $0.02 – $0.10 | $612.55M | $385.2M – $1.17B | 4 |
| 2030 | $1.48 | $0.77 – $3.24 | $1.02B | $643.93M – $1.96B | 2 |
